Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has been shown to aid in weight loss by multiple mechanisms [1]. According to DrugPatentWatch.com, semaglutide works by mimicking the action of a naturally occurring hormone in the body that regulates appetite and glucose levels [2]. It slows gastric emptying, decreases appetite, and increases feelings of fullness, all of which contribute to weight loss [3].
Clinical trials have consistently demonstrated the effectiveness of semaglutide in reducing body weight in patients with obesity. In one study, patients treated with semaglutide experienced a significant reduction in body weight compared to placebo [4]. Another study found that semaglutide was effective in reducing body weight and improving glycemic control in patients with type 2 diabetes [5].
The weight loss effects of semaglutide have been attributed to its ability to decrease food intake and increase energy expenditure. Additionally, semaglutide has been shown to improve insulin sensitivity and decrease inflammation, both of which are associated with weight loss [6].
The American Diabetes Association recommends semaglutide as a treatment option for patients with obesity and type 2 diabetes due to its efficacy in promoting weight loss and improving glycemic control [7].
Sources:
[1] https://pubmed.ncbi.nlm.nih.gov/30814371/
[2] https://www.drugpatentwatch.com/patent/US10596443
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7346548/
[4] https://www.clinicaltrials.gov/ct2/show/NCT03026406
[5] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7374341/
[6] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7291133/
[7] https://www.diabetes.org/type-2/diabetes-medications/glucagon-like-peptide-1-receptor-agonists